Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03401697 · ClinicalTrials.gov registry record
Eliminating Hepatitis C Virus
A clinical trial of Type 2 Diabetes and HIV, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT03401697: Completed study of Type 2 Diabetes and HIV, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03401697 is a study of Type 2 Diabetes and HIV that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 52 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03401697, a study of Type 2 Diabetes and HIV, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Initially, HCV Informatics (C-IT) will be used to filter the EMR data of the one million people who receive care at Mount Sinai and identify candidates for HCV testing (baby boomers, patients with HIV infection) and candidates for HCV treatment (patients with positive test results for HCV RNA and no record of treatment).once treatment candidates have been identified through this proactive approach, their providers will be directly notified. HCV champions and patient navigators will be used to further lower barriers to the delivery of HCV care. They will be co-located at non-hepatology care sites and will help deliver open-label HCV treatment as part of standard medical care to 500 HIV/HCV co-infected patients and 200 patients with type 2 diabetes.
Primary Outcome
Change in the Number of Patients with sCD163 above the upper limit of normal at 3 years from baseline
Conditions Studied
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-01-23 |
| Est. Completion | 2021-03-01 |
What the finished NCT03401697 record still lists
NCT03401697 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 0 interventions.
NCT03401697 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03401697 about?
NCT03401697 is a clinical study titled "Eliminating Hepatitis C Virus". Initially, HCV Informatics (C-IT) will be used to filter the EMR data of the one million people who receive care at Mount Sinai and identify candidates for HCV testing (baby boomers, patients with HIV infection) and candidates for HCV treatment (patients with positive test results for HCV RNA and no...
What is the current status of trial NCT03401697?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2018-01-23. Estimated completion is 2021-03-01.
What conditions does trial NCT03401697 study?
This clinical trial studies the following conditions: Type 2 Diabetes, HIV, Hepatitis C.
Who is sponsoring clinical trial NCT03401697?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03401697 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03401697's enrollment target sits among peer trials
52 210th of 327 higher than 117 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI